Vimarsana
Biggest News Aggregation in the World

Page 2 - Available Methods News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Available Methods. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Available Methods Today - Breaking & Trending Today

Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial - Vimarsana News

Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

* Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial... | May 17, 2023

TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial - Vimarsana News

TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy ... | May 17, 2023

TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer - Vimarsana News

TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer

Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in Japan for early lung cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in Japan for early lung cancer

Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer - Vimarsana News

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer

07.03.2022 - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) - (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) ...